Heptares, using its StaR technology, has determined that approximately 100 GPCR targets across a range of diseases including cancer, fibrosis, inflammation, respiratory, pain, are suitable and commercially viable as antibody targets. Heptares is now leveraging its StaR platform to generate antigens for GPCR antibody drug discovery via partnerships with MedImmune and other companies.
Malcolm Weir, Heptares chief executive officer, said, "The delivery of a StaR for each nominated target is an important achievement in the successful research phase of our collaboration with MedImmune. The StaR proteins will be used by MedImmune as antigens, for which novel therapeutic antibodies can be generated. The ability of our StaR platform to generate antigen for antibody drug discovery, as exemplified by the success of our collaboration with MedImmune, highlights the potential of this technology to transform GPCR-targeted drug design and development."